Remarkable results of rubicatin in the treatment of lung cancer

Lurbinectedin (Lurbinectedin), as an innovative lung cancer treatment drug, has been rigorously verified in multiple rounds of clinical trials, confirming its excellent therapeutic effect. Rubicatin has shown extraordinary efficacy in patients with metastatic small cell lung cancer (SCLC) whose disease has progressed despite platinum-based chemotherapy.

Rubicardin's application in the treatment of SCLC has received accelerated approval from regulatory agencies, mainly due to its excellent performance in overall response rate and response duration. The U.S. Food and Drug Administration (FDA) approved rubicatin based on a Phase 2 open-label, single-arm study involving 105 SCLC patients. The study was conducted at 26 hospitals in six European countries and the United States. Patients were treated with rubicatin at a dose of 3.2 mg per square meter of body surface area, administered by intravenous infusion, with each infusion lasting 60 minutes and repeated every 21 days until disease progression or toxicity reached unacceptable levels. The study results showed that the overall response rate reached 35%, and the median response duration was 5.3 months.

Although Rubicatin is not currently available in the Chinese market, patients who are in urgent need of this drug can purchase it through overseas channels or seek help from professional overseas medical consulting companies. Rubicatin currently available on the market is the original version produced by the Spanish pharmaceutical company PharmamanMar. The 4 mg dosage of the drug is priced at NT$34,000 per box in Singapore and NT$91,000 per box in the United States.

Overall, rubicatin has shown impressive efficacy in the treatment of small cell lung cancer. Whether in terms of overall response rate, disease control rate, or multiple evaluation indicators such as duration of response and progression-free survival, rubicatin has demonstrated its significant advantages and potential as an innovative drug.